Mirum to buy Bluejay for up to $820m in rare liver disease push
Mirum Pharmaceuticals has agreed to acquire Bluejay Therapeutics in a deal worth up to $820m, adding a Phase III liver…
Infectious Diseases
-
-
“Sharp” funding cuts disrupt PrEP access to millions of HIV patients
The World Health Organization (WHO) has called for access expansion to newly approved human immunodeficiency virus (HIV) medication amid “sharp…
-
MSD pays up to nearly $600m for Evaxion’s mystery vaccine candidate
Merck & Co (MSD) has taken the first of two possible plunges in its ongoing collaboration with Evaxion, gaining the…
-
Bavarian Nordic’s Vimkunya makes UK debut amid Ixchiq suspension
Bavarian Nordic has launched its chikungunya vaccine, Vimkunya, in the UK. This follows the sharp rise in travel-related disease incidences…
-
Chickenpox jab to be included on England’s childhood vaccination programme
England's National Health Service (NHS) will offer the chickenpox vaccine to children from January 2026, marking the first time the…
-
FDA bans Ixchiq in the US, sending Valneva shares plummeting
The US Food and Drug Administration (FDA) has suspended the licence for Valneva’s chikungunya vaccine Ixchiq, just two weeks after…
-
Gilead wins positive European approval opinion for twice-yearly HIV injection
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Gilead Sciences’ lenacapavir, a…
-
WHO endorses Gilead’s Yeztugo for HIV prevention
The World Health Organization (WHO) is recommending the use of Gilead Sciences’ newly approved injectable version of lenacapavir to fight…
-
GSK eyes FDA label expansion for RSV vaccine Arexvy to include younger patients
GSK has applied to the US Food and Drug Administration (FDA) to extend use of its respiratory syncytial virus (RSV)…
-
Research warns of rising HIV cases in Africa amid global funding cuts
Global funding cuts, including those made by the Trump administration, are set to increase cases of human immunodeficiency virus (HIV)…
